Altimmune Plunges 14.56% on Goldman Sachs Downgrade

On July 10, 2025, Altimmune's stock experienced a significant drop of 14.56% in pre-market trading, sparking concerns among investors about the company's future prospects.

Goldman Sachs recently downgraded Altimmune's stock to a Sell rating, citing concerns over the company's pipeline and financial performance. This move by the investment bank has raised questions about the viability of Altimmune's current strategy and its ability to deliver on its promises.

Additionally, Altimmune's recent clinical trial results have been underwhelming, with several key studies failing to meet their primary endpoints. This has led to a loss of confidence among investors, who are now questioning the company's ability to bring new drugs to market.

Despite these challenges, Altimmune has maintained that it remains committed to its mission of developing innovative therapies for patients in need. The company has stated that it is working diligently to address the issues raised by Goldman Sachs and to improve its clinical trial outcomes.